Prognostic role of the stromal cell derived factor-1 in patients with hepatitis B virus-related acute-on-chronic liver failure

Table 2 The baseline data of survivors and non-survivors with hepatitis B virus-related acute-on-chronic liver failure receiving standard medical treatment

	Survivors (n = 11)	Non-survivors (n = 19)	P value
Age (yr)	40 ± 13	44 ± 14	0.467
Gender (male/female)	8/3	17/2	0.327
Albumin (g/L)	30.9 ± 5.2	29.1 ± 4.1	0.305
ALT (U/L)	471.8 ± 319.3	359.8 ± 319.9	0.189
AST (U/L)	415.2 ± 279.7	331.6 ± 232.1	0.451
TBIL (µmol/L)	315.9 ± 182.8	419.6 ± 168.4	0.126
DBIL (µmol/L)	173.5 ± 89.6	241.3 ± 117.1	0.109
INR	2.0 ± 0.4	2.9 ± 0.9	0.001
CREA (µmol/L)	84.4 ± 40.4	94.3 ± 62.9	0.747
HBVDNA (log10 copies/mL)	4.8 ± 1.3	4.7 ± 1.8	0.808
HBeAg (+)/HBeAg (-)	5/6	6/13	0.696
MELD score	23.2 ± 6.8	28.8 ± 7.0	0.041

Values are given as mean ± SD. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBIL: Total bilirubin; DBIL: Direct bilirubin; INR: International normalized ratio; CREA: Creatinine; HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen.